Second allogeneic transplantation using unrelated cord blood for relapsed hematological malignancies after allogeneic transplantation

References

• Thakar MS, Forman SJ. ASH evidence-based guidelines: is there a role for second allogeneic transplant after relapse? Hematology Am Soc Hematol Educ Program 2009:414–418.
   PubMedGoogle Scholar
• Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood 2013;122:491–498.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004;104:3813–3820.
   PubMed Web of Science ®Google Scholar
• Konuma T, Ooi J, Takahashi S, et al. Second myeloablative allogeneic stem cell transplantation (SCT) using cord blood for leukemia relapsed after initial allogeneic SCT. Leuk Res 2009;33:840–842.
   PubMed Web of Science ®Google Scholar
• Isoyama K, Ohnuma K, Ikuta K, et al. Unrelated cord blood transplantation for second hemopoietic stem cell transplantation. Pediatr Int 2003;45:268–274.
   PubMed Web of Science ®Google Scholar
• Oda M, Isoyama K, Ito E, et al. Survival after cord blood transplantation from unrelated donor as a second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Int J Hematol 2009;89:374–382.
   PubMed Web of Science ®Google Scholar
• Ueki T, Sumi M, Sato K, et al. Reduced-intensity cord blood transplantation without prior remission induction therapy induces durable remission in adult patients with relapsed acute leukemia after the first allogeneic transplantation. Eur J Haematol 2011;86:268–271.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912–2919.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825–828.
   PubMed Web of Science ®Google Scholar
• Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204–217.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009;15:1628–1633.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013;48:452–458.
   PubMed Web of Science ®Google Scholar
• Pawson R, Potter MN, Theocharous P, et al. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant. Br J Haematol 2001;115:622–629.
   PubMed Web of Science ®Google Scholar
• Konuma T, Kato S, Ooi J, et al. Third allogeneic stem cell transplantation (SCT) using unrelated cord blood for relapsed acute leukemia after second allogeneic SCT. Int J Hematol 2015;101:392–397.
   PubMed Web of Science ®Google Scholar
• Radich JP, Sanders JE, Buckner CD, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993;11:304–313.
   PubMed Web of Science ®Google Scholar
• Michallet M, Tanguy ML, Socié G, et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de moelle (SFGM). Br J Haematol 2000;108:400–407.
   PubMed Web of Science ®Google Scholar
• Eapen M, Giralt SA, Horowitz MM, et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004;34:721–727.
   PubMed Web of Science ®Google Scholar
• Kato M, Horikoshi Y, Okamoto Y, et al. Second allogeneic hematopoietic SCT for relapsed ALL in children. Bone Marrow Transplant 2012;47:1307–1311.
   PubMed Web of Science ®Google Scholar
• Christopoulos P, Schmoor C, Waterhouse M, et al. Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML. Bone Marrow Transplant 2013;48:901–907.
   PubMed Web of Science ®Google Scholar
• Kishi K, Takahashi S, Gondo H, et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplant 1997;19:461–466.
   PubMed Web of Science ®Google Scholar
• Bosi A, Laszlo D, Labopin M, et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001;19:3675–3684.
   PubMed Web of Science ®Google Scholar
• Hosing C, Saliba RM, Shahjahan M, et al. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant 2005; 36:157–162.
   PubMed Web of Science ®Google Scholar
• Christopeit M, Kuss O, Finke J, et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol 2013;31:3259–3271.
   PubMed Web of Science ®Google Scholar
• Meshinchi S, Leisenring WM, Carpenter PA, et al. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biol Blood Marrow Transplant 2003; 9:706–713.
   PubMed Web of Science ®Google Scholar
• Hill BT, Bolwell BJ, Rybicki L, et al. Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants. Biol Blood Marrow Transplant 2010;16:1738–1746.
   PubMed Web of Science ®Google Scholar
• Shaw BE, Mufti GJ, Mackinnon S, et al. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant 2008;42:783–789.
   PubMed Web of Science ®Google Scholar
• Duus JE, Stiff PJ, Choi J, et al.Second allografts for relapsed hematologic malignancies: feasibility of using a different donor. Bone Marrow Transplant 2005;35:261–264.
   PubMed Web of Science ®Google Scholar
• Tischer J, Engel N, Fritsch S, et al. Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. Bone Marrow Transplant 2014;49:895–901.
   PubMed Web of Science ®Google Scholar